{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-342328","form_type":"8-K","ticker":"SEPN","cik":"0001984086","company_name":"Septerna, Inc.","filed_at":"2026-08-10T20:03:56+00:00","discovered_at":"2026-08-10T20:05:01.445787+00:00","generated_at":"2026-08-10T20:05:10.935816+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Septerna Q2 2026: net loss $13.0M, cash $516.5M, SEP-479 half-life supports once-daily dosing","bullets":["Cash, equivalents and marketable securities totaled $516.5M as of June 30, 2026; expected to fund operations into 2029.","Q2 2026 revenue of $26.7M from Novo Nordisk collaboration vs $0.1M from Vertex a year ago; net loss narrowed to $13.0M from $24.8M.","SEP-479 Phase 1 observed elimination half-life ~3-4 days supports once-daily dosing; SAD/MAD data expected Q1 2027.","SEP-631 showed positive Phase 1 results; company evaluating signal-finding studies in mast cell-driven diseases; TSHR program advancing."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-342328","json":"https://secwatch.observer/filing/0001193125-26-342328.json","markdown":"https://secwatch.observer/filing/0001193125-26-342328.md","text":"https://secwatch.observer/filing/0001193125-26-342328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1984086/000119312526342328/0001193125-26-342328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1984086/000119312526342328/sepn-20260810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-10T20:05:10.935816+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}